cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Atea Pharmaceuticals Inc
22 own
23 watching
Current Price
$3.16
$0.06
(1.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
272.73M
52-Week High
52-Week High
4.60000
52-Week Low
52-Week Low
2.75
Average Volume
Average Volume
0.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
26.9871
iconMarket Capitalization272.73M
icon52-Week High4.60000
icon52-Week Low2.75
iconAverage Volume0.34M
iconDividend Yield--
iconP/E Ratio26.9871
What does the Atea Pharmaceuticals Inc do?
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.
Read More
How much money does Atea Pharmaceuticals Inc make?
News & Events about Atea Pharmaceuticals Inc.
Globe Newswire
1 year ago
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination statusBOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage ...
Ticker Report
1 year ago
Atea Pharmaceuticals (NASDAQ:AVIR Get Rating) had its target price reduced by JPMorgan Chase Co. from $12.00 to $8.00 in a report published on Thursday morning, Benzinga reports. They currently have a neutral rating on the stock. Several other equities research analysts also recently ...
Globe Newswire
1 year ago
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36th ...
Globe Newswire
2years ago
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination ...
Zolmax
2years ago
Atea Pharmaceuticals (NASDAQ:AVIR Get Rating) had its price objective lowered by JPMorgan Chase & Co. from $10.00 to $8.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the stock. A number of other research analysts have also ...
Frequently Asked Questions
Frequently Asked Questions
What is Atea Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Atea Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Atea Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Atea Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Atea Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Atea Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Atea Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Atea Pharmaceuticals Inc?
plus_minus_icon
What percentage is Atea Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Atea Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.16
$0.06
(1.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$0.38
$-0.00 (-0.29 %)
FOGHORN THERAPEUTICS INC
FOGHORN THERAPEUTICS INC
$4.06
$-0.32 (-7.31 %)
Mesoblast
Mesoblast
$18.27
$0.25 (1.39 %)
SUMMIT THERAPEUTICS INC
SUMMIT THERAPEUTICS INC
$23.76
$-0.89 (-3.61 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$0.38
$-0.00 (-0.29 %)
FOGHORN THERAPEUTICS INC
FOGHORN THERAPEUTICS INC
$4.06
$-0.32 (-7.31 %)
Mesoblast
Mesoblast
$18.27
$0.25 (1.39 %)
SUMMIT THERAPEUTICS INC
SUMMIT THERAPEUTICS INC
$23.76
$-0.89 (-3.61 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00